Testing effectiveness (Phase 2)Looking for participantsNCT06788912
What this trial is testing
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Who this might be right for
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC 60